DCBLD1 and prostate carcinoma: Upregulation of the integrin signaling pathway was not observed for colorectal and prostate cancers, the prognosis was similar for patients with high or low DCBLD1 expression within these cohorts, suggesting that DCBLD1 activity is cell-type dependent.